Cure Research Program News Today

New data show that Black women with node positive HR+/HER2- breast cancer have worse outcomes than their white counterparts, although the difference was no longer significant after adjustment for BMI.

Certain patients with hormone receptor-positive, HER2-negative breast cancer can safely forgo adjuvant chemotherapy, a study suggests.

Some postmenopausal women with breast cancer do not benefit from chemotherapy when it’s added to hormone therapy, according to initial results of a clinical trial. The findings apply to postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low. The findings may save tens of thousands of postmenopausal women each year the time, m...